Correction to: Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis.

导出 OA

翻译打印收藏纠错

作者： Mark,Gudesblatt ^[1] ; Karl,Wissemann ^[1] ; Myassar,Zarif ^[1] ; Barbara,Bumstead ^[1] ; Lori,Fafard ^[1] ; Jeffrey,Wilken ^[2] ; Karen,Blitz ^[1] ; Marijean,Buhse ^[1] ; Sourav,Santra ^[3] ; Christophe,Hotermans ^[3] ; Lily,Lee ^[4]

作者单位： South Shore Neurologic Associates, Patchogue, NY, USA. ^[1] Washington Neuropsychology Research Group LLC, Fairfax, VA, USA. ^[2] Biogen, 225 Binney Street, Cambridge, MA, 02142, USA. ^[3] Biogen, 225 Binney Street, Cambridge, MA, 02142, USA. lily.lee@biogen.com. ^[4]

DOI 10.1007/s40263-018-0574-9

PMID 30244406

发布时间 2020-10-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览11

CNS drugs

2018年32卷12期

1183页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Correction to: Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis.

CNS drugs

相似文献

CNS drugs

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Correction to: Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis.

CNS drugs

相似文献

CNS drugs

相关期刊

检索历史清除